Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.

El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R.

Br J Cancer. 2020 Jan 14. doi: 10.1038/s41416-019-0710-4. [Epub ahead of print]

PMID:
31937927
2.

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.

Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ.

Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28.

PMID:
31462408
3.

Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.

El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R.

Br J Cancer. 2019 Oct;121(7):556-566. doi: 10.1038/s41416-019-0542-2. Epub 2019 Aug 16. Erratum in: Br J Cancer. 2020 Jan 14;:.

4.

Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.

López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H.

JCO Clin Cancer Inform. 2019 Apr;3:1-16. doi: 10.1200/CCI.18.00075.

5.

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI.

Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14.

PMID:
30765391
6.

Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process.

Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL.

Cytotherapy. 2019 Mar;21(3):307-314. doi: 10.1016/j.jcyt.2018.11.004. Epub 2018 Dec 1.

PMID:
30509772
7.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

8.

Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy.

Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H.

Sci Rep. 2018 Jun 21;8(1):9474. doi: 10.1038/s41598-018-27718-1.

9.

Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy.

Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H.

Converg Sci Phys Oncol. 2017 Sep;3(3). pii: 034001. doi: 10.1088/2057-1739/aa7269. Epub 2017 Jun 15.

10.

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.

Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2018 Apr 25;13(4):e0196033. doi: 10.1371/journal.pone.0196033. eCollection 2018.

11.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA.

Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.

12.

Hypoxia and acidosis: immune suppressors and therapeutic targets.

Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ.

Immunology. 2018 Jul;154(3):354-362. doi: 10.1111/imm.12917. Epub 2018 Mar 30. Review.

13.

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.

Mahajan NP, Malla P, Bhagwat S, Sharma V, Sarnaik A, Kim J, Pilon-Thomas S, Weber J, Mahajan K.

Oncotarget. 2017 Nov 10;8(63):106352-106368. doi: 10.18632/oncotarget.22374. eCollection 2017 Dec 5.

14.

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.

Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA.

J Immunother Cancer. 2016 Oct 18;4:61. doi: 10.1186/s40425-016-0164-7. eCollection 2016.

15.

Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.

Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S.

Oncotarget. 2016 Jun 21;7(25):37893-37905. doi: 10.18632/oncotarget.9247.

16.

Tipping the Balancing ACT.

Pilon-Thomas S, Ruffell B.

Cancer Cell. 2016 Sep 12;30(3):367-368. doi: 10.1016/j.ccell.2016.08.012.

17.

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.

Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2016 Apr 6;11(4):e0153053. doi: 10.1371/journal.pone.0153053. eCollection 2016.

18.

M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.

Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA.

Neuro Oncol. 2016 Aug;18(8):1088-1098. doi: 10.1093/neuonc/now006. Epub 2016 Mar 8.

19.

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ.

Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552.

20.

Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties.

Chacon JA, Sarnaik AA, Pilon-Thomas S, Radvanyi L.

Oncoimmunology. 2015 Jul 1;4(12):e1040219. eCollection 2015 Dec.

21.

Murine pancreatic adenocarcinoma reduces Ikaros expression and disrupts T cell homeostasis.

Nelson N, Xiang S, Zhang X, Gilvary D, Djeu J, Husain K, Malafa M, Vohra N, Pilon-Thomas S, Ghansah T.

PLoS One. 2015 Jan 28;10(1):e0115546. doi: 10.1371/journal.pone.0115546. eCollection 2015.

22.

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L.

Clin Cancer Res. 2015 Feb 1;21(3):611-21. doi: 10.1158/1078-0432.CCR-14-1934. Epub 2014 Dec 3.

23.

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG.

Oncoimmunology. 2013 Sep 1;2(9):e25581. Epub 2013 Jul 3.

24.

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.

Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P.

Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. No abstract available.

25.

Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2013 Jul 17;8(7):e68561. doi: 10.1371/journal.pone.0068561. Print 2013.

26.

Examination of MARCO activity on dendritic cell phenotype and function using a gene knockout mouse.

Komine H, Kuhn L, Matsushita N, Mulé JJ, Pilon-Thomas S.

PLoS One. 2013 Jul 1;8(7):e67795. doi: 10.1371/journal.pone.0067795. Print 2013.

27.

Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.

Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S.

Cancer Immunol Immunother. 2013 Jun;62(6):1083-91. doi: 10.1007/s00262-013-1407-9. Epub 2013 Apr 19.

28.

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

29.

Immunotherapy for gastrointestinal malignancies.

Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA.

Cancer Control. 2013 Jan;20(1):32-42. Review.

30.

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S.

J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.

31.

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA.

J Immunother. 2012 Oct;35(8):615-20.

32.

Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function.

Pilon-Thomas S, Nelson N, Vohra N, Jerald M, Pendleton L, Szekeres K, Ghansah T.

PLoS One. 2011;6(11):e27729. doi: 10.1371/journal.pone.0027729. Epub 2011 Nov 22.

33.

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ.

J Immunol. 2010 Apr 1;184(7):3442-9. doi: 10.4049/jimmunol.0904114. Epub 2010 Mar 1.

34.

Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Matsushita N, Komine H, Grolleau-Julius A, Pilon-Thomas S, Mulé JJ.

Cancer Immunol Immunother. 2010 Jun;59(6):875-84. doi: 10.1007/s00262-009-0813-5. Epub 2010 Jan 8.

35.

TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model.

Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S.

Cancer Immunol Immunother. 2010 May;59(5):729-36. doi: 10.1007/s00262-009-0793-5.

36.

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.

Radkevich-Brown O, Piechocki MP, Back JB, Weise AM, Pilon-Thomas S, Wei WZ.

Cancer Immunol Immunother. 2010 Mar;59(3):409-17. doi: 10.1007/s00262-009-0760-1.

37.

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.

Koike N, Pilon-Thomas S, Mulé JJ.

J Immunother. 2008 May;31(4):402-12. doi: 10.1097/CJI.0b013e31816cabbb.

PMID:
18391755
38.

Comparative methodologies of regulatory T cell depletion in a murine melanoma model.

Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI.

J Immunol Methods. 2008 Apr 20;333(1-2):167-79. doi: 10.1016/j.jim.2008.01.012. Epub 2008 Feb 13.

39.

Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.

Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI.

J Immunother. 2006 Jul-Aug;29(4):381-7.

PMID:
16799333
40.

Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.

Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mulé JJ.

Cancer Immunol Immunother. 2006 Oct;55(10):1238-46. Epub 2005 Nov 29.

PMID:
16315029
41.

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H.

Nat Med. 2005 Dec;11(12):1314-21. Epub 2005 Nov 20.

PMID:
16288283
42.

Dendritic cell-based therapeutics for breast cancer.

Pilon-Thomas SA, Verhaegen ME, Mulé JJ.

Breast Dis. 2004;20:65-71. Review.

PMID:
15687708
43.

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.

Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.

Biol Blood Marrow Transplant. 2004 Aug;10(8):524-33.

Supplemental Content

Loading ...
Support Center